An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma

Roche

Status: Completed

Conditions: Renal Cell Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01351571

ML25251

Details and patient eligibility

About

This observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with interferon alpha-2a as first-line treatment in patients with advanced and/or metastatic renal cell carcinoma. Data will be collected from each patient as per routine clinical practice of the Investigator (maximum of 52 weeks, until disease progression /unacceptable toxicity or withdrawal of consent) and/or based on the local label.

Enrollment: 5 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/= 18 years of age
• Advanced and/or metastatic renal cell carcinoma
• Receiving first-line treatment with Avastin and interferon alpha-2a according to standard of care and current local label
• At least one measurable and non-measurable lesion according to RECIST criteria
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• Adequate bone marrow, renal and liver function

Exclusion criteria

• Contraindications to Avastin and/or interferon alpha-2a as per local label

Trial design

5 participants in 1 patient group

Cohort